Trial Profile

A Randomized Trial on Efficacy and Safety of Ozanimod for the Treatment of COVID-19 Patients Requiring Oxygen Support - A Pilot Trial

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 31 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ozanimod (Primary) ; Anticoagulants; Antipyretics; Antivirals; Corticosteroids; Immunomodulators
Indications COVID-19 pneumonia; Hypoxaemia
Focus Therapeutic Use
Acronyms COZI

Most Recent Events

26 Oct 2023 Primary endpoint (Daily Patient progression assessed with the World Health Organization-adapted 6-points ordinal scale) has not been met according to results published in the Chest.
26 Oct 2023 Results published in the Chest
13 May 2022 Status changed from recruiting to discontinued.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com